Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial
Posted inClinical Updates news Psychiatry

Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial

A phase 2 trial in adults with major depressive disorder demonstrated that ammoxetine at 40 mg/d and 60 mg/d significantly improved depressive symptoms compared to placebo and was generally well tolerated, offering a novel treatment option with potentially fewer adverse effects.
Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence
Posted inClinical Updates news Psychiatry

Theta Burst Stimulation of the Temporo-Parietal Cortex for Persistent Auditory Hallucinations in Schizophrenia: A Comprehensive Review of a Phase 3 Randomised Multicentre Trial and Contextual Evidence

This review synthesizes evidence on bilateral continuous theta burst stimulation (cTBS) of the temporo-parietal cortex for persistent auditory verbal hallucinations (AVH) in schizophrenia, focusing on a landmark German phase 3 trial demonstrating safety and modest efficacy.
Personalized High-Definition Transcranial Direct Current Stimulation: A Promising Rapid Intervention for Moderate to Severe Depression
Posted inClinical Updates news Psychiatry Specialties

Personalized High-Definition Transcranial Direct Current Stimulation: A Promising Rapid Intervention for Moderate to Severe Depression

A randomized clinical trial demonstrates that personalized high-definition transcranial direct current stimulation (HD-tDCS) significantly improves mood in patients with moderate to severe depression, showing faster and comparable effect sizes to conventional therapies and also reducing anxiety symptoms.
Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials
Posted inPsychiatry Specialties

Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials

A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use disorder treatment.